Clinical momentum Theranos, a biotech research firm with ongoing phase trials in radiopharmaceuticals, presents sales opportunities to suppliers and CROs supporting radiotherapy, imaging agents, and companion diagnostics in oncology.

Strategic partnerships Recent collaborations and supply agreements in radiopharmaceuticals indicate openness to tiered partnerships with device manufacturers, radiochemistry suppliers, and contract manufacturers to scale with clinical trials and future commercialization.

Focused oncology A strong emphasis on brain metastases imaging and advanced prostate cancer radiopharmaceuticals highlights potential for diagnostic imaging equipment, radiolabeling reagents, and theranostics platforms targeting high-need cancer indications.

Funding readiness With existing revenue and substantial funding, Theranos may be receptive to strategic investments, grant support, or co-development deals that accelerate pipeline milestones and expand clinical trial capacity.

Global expansion Clinical programs and press on international trial activity suggest opportunities for global distribution partnerships, regulatory consulting, and regional logistics solutions for radiopharmaceuticals and associated imaging modalities.